However, in the study by Partelli et al. including 49 consecutive pancreatic NET patients (of all grades), the authors concluded that therapy was not influenced by the performance of combined SST and FDG PET/CT, and suggested a potential higher impact in the setting of pancreatic NET with Ki‐67 >10%.36 Here, MKI67 is linked to pancreatic neuroendocrine tumor.